VOGX (Vogenx) EV-to-EBITDA: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vogenx's enterprise value is $196.52 Mil. Vogenx does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's EV-to-EBITDA at this moment.

The historical rank and industry rank for Vogenx's EV-to-EBITDA or its related term are showing as below:

VOGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -136.56   Med: 0   Max: 0
Current: -136.56
VOGX's EV-to-EBITDA is ranked worse than
100% of 400 companies
in the Biotechnology industry
Industry Median: 13.485 vs VOGX: -136.56

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-14), Vogenx's stock price is $14.09. Vogenx does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Vogenx  (NAS:VOGX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Vogenx's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.09/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Vogenx EV-to-EBITDA Related Terms

Vogenx EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Vogenx's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx EV-to-EBITDA Chart

Vogenx Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Vogenx Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

VOGX vs : EV-to-EBITDA Comparison

For the Biotechnology subindustry, Vogenx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vogenx EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vogenx's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vogenx's EV-to-EBITDA falls into.


VOGX
8GF Score
Vogenx Inc VOGX
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx EV-to-EBITDA Calculation

Vogenx's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=196.517/
=

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price